Jim Cramer Predicts Novo Nordisk Market Share Loss to Eli Lilly

Jim Cramer expressed his belief that Novo Nordisk is poised to lose significant market share in the pill segment to competitor Eli Lilly, highlighting the competitive landscape in the pharmaceutical industry.